作者
Partow Kebriaei, Claudio Anasetti, Mei-Jie Zhang, Hai-Lin Wang, Ibrahim Aldoss, Marcos de Lima, H Jean Khoury, Brenda M Sandmaier, Mary M Horowitz, Andrew Artz, Nelli Bejanyan, Stefan Ciurea, Hillard M Lazarus, Robert Peter Gale, Mark Litzow, Christopher Bredeson, Matthew D Seftel, Michael A Pulsipher, Jaap-Jan Boelens, Joseph Alvarnas, Richard Champlin, Stephen Forman, Vinod Pullarkat, Daniel Weisdorf, David I Marks, William Hogan, Minoo Battiwalla, Edward Copelan, Gerhard Hildebrandt, Sid Ganguly, Navneet Majhail, Ann Woolfrey, Ian Nivison-Smith, Mark Hertzberg, Miguel Angel Diaz, Ann Jakubowski, Celalettin Ustun, Agnes Yong, Cesar Freytes, Zachariah DeFilipp, Yoshi Inamoto, Jean-Yves Cahn, Bipin Savani, Jean Yared, Ashish Bajel, Ulrike Bacher, Geoffrey Uy, David Rizzieri, Matthew Wieduwilt, Kirk Schultz, Michael Grunwald, Rammurti Kamble, Muna Qayed, Jonathan Brammer, Karen Ballen, Nandita Khera, Harry Schouten, Marc Bierings, Christopher Kanakry, William Allen Wood, Ayman Saad, Lynn Savoie, Betty Ky Hamilton, Mahmoud Aljurf, Ravi Vij, Attaphol Pawarode, Richard Olsson, B Mona Wirk, Amer Beitinjaneh, Sachiko Seo, Jan Cerny, Gorgun Akpek, Maxim Norkin, Taiga Nishihori, Aleksandr Lazaryan, Mitchell Sabloff
发表日期
2018/4/1
期刊
Biology of Blood and Marrow Transplantation
卷号
24
期号
4
页码范围
726-733
出版商
Elsevier
简介
Total body irradiation (TBI) has been included in standard conditioning for acute lymphoblastic leukemia (ALL) before hematopoietic cell transplantation (HCT). Non-TBI regimens have incorporated busulfan (Bu) to decrease toxicity. This retrospective study analyzed TBI and Bu on outcomes of ALL patients 18–60 years old, in first or second complete remission (CR), undergoing HLA-compatible sibling, related, or unrelated donor HCT, who reported to the Center for International Blood and Marrow Transplant Research from 2005 to 2014. TBI plus etoposide (25%) or cyclophosphamide (75%) was used in 819 patients, and intravenous Bu plus fludarabine (41%), clofarabine (30%), cyclophosphamide (15%), or melphalan (13%) was used in 299 patients. Bu-containing regimens were analyzed together, since no significant differences for patient outcomes were noted between them. Bu patients were older, with better …
学术搜索中的文章
P Kebriaei, C Anasetti, MJ Zhang, HL Wang, I Aldoss… - Biology of blood and marrow transplantation, 2018
P Kebriaei, C Anasetti, MJ Zhang, HL Wang, I Aldoss… - Blood, 2016